Host-targeted pan-respiratory antiviral small molecule therapeutics

Inventors

Lingappa, Vishwanath R. • Paulvannan, Kumarapandian

Assignees

Prosetta Biosciences Inc

Abstract

Described herein are compounds, pharmaceutical compositions and methods of using these compounds and pharmaceutical compositions for treating and/or preventing conditions such as, for example, those caused by any viral family causing respiratory viral disease, including specifically coronaviruses and influenza viruses.

Core Innovation

The invention relates to a compound having the structure shown in the claim, together with pharmaceutically acceptable salts, hydrates or solvates thereof. The disclosed compound family is represented by multiple specific chemical structures that share a common scaffold with substituted heteroaromatic or bicyclic cores, amide or carboxamide functionality, and variable aryl and heterocycle substituents.

Across the series, the structures include sulfonamide, sulfone, or sulfonyl-related groups, halogen substituents such as Cl, methoxy or hydroxy groups, and fluorinated substituents such as CF3-substituted phenyls and difluoromethylated substituents. The examples are presented as closely related analogs within the same general structural framework.

The disclosure also provides chemical structure depictions and related synthetic preparations for multiple numbered compounds and intermediates, with LCMS (ESI+) characterization reported for several compounds and intermediates. The document frames these structures as members of the claimed compound series and, in some instances, as compounds prepared through stepwise transformations and interconversion of intermediates.

Claims Coverage

The independent claim set is directed to a single compound having a defined chemical structure and expressly includes pharmaceutically acceptable salts, hydrates or solvates. Dependent claims further add a pharmaceutical composition and therapeutic methods for treating influenza and coronavirus infections by administering either the compound or the pharmaceutical composition, yielding six inventive features in total.

Coverage centers on the defined compound structure and its pharmaceutically acceptable salts, hydrates or solvates, and extends to pharmaceutical compositions with a pharmaceutically acceptable vehicle and to methods of treating influenza and coronavirus infections by administering either the compound or the pharmaceutical composition.

Stated Advantages

Documented Applications